These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28425014)

  • 1. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    Breast Cancer; 2017 Nov; 24(6):748-755. PubMed ID: 28425014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression discordances and clinical values of ER, PR, HER-2 and Ki-67 in primary and metastatic breast cancer].
    Yuan Y; Hu SN; Gao J; Yu Q; Hu YQ; Xu XY; Gao ZG; Zhang J; Zhang Z; Teng Y; Zhang LL
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):681-685. PubMed ID: 31550858
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis.
    Loehberg CR; Almstedt K; Jud SM; Haeberle L; Fasching PA; Hack CC; Lux MP; Thiel FC; Schrauder MG; Brunner M; Bayer CM; Hein A; Heusinger K; Heimrich J; Bani MR; Renner SP; Hartmann A; Beckmann MW; Wachter DL
    Breast Cancer Res Treat; 2013 Apr; 138(3):899-908. PubMed ID: 23479421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.
    Lattanzio R; Iezzi M; Sala G; Tinari N; Falasca M; Alberti S; Buglioni S; Mottolese M; Perracchio L; Natali PG; Piantelli M
    BMC Cancer; 2019 Jul; 19(1):747. PubMed ID: 31362705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases.
    Thangarajah F; Enninga I; Malter W; Hamacher S; Markiefka B; Richters L; Krämer S; Mallmann P; Kirn V
    Anticancer Res; 2017 Apr; 37(4):1957-1964. PubMed ID: 28373466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
    Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
    Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers.
    Kim HS; Park S; Koo JS; Kim S; Kim JY; Nam S; Park HS; Kim SI; Park BW
    PLoS One; 2016; 11(3):e0151054. PubMed ID: 26954364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value and Influence of Receptor Conversion on Treatment Regimen in Metastatic Breast Cancer at the First Time of Recurrence.
    Shen J; Xu L; Shi J; Zhao L; Shi S; Feng J; Han X; Shi Y; Wei Q; Wang D; Sun M; Mi X; Teng Y
    Oncol Res Treat; 2020; 43(11):620-627. PubMed ID: 32966998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis.
    Wu SG; Li H; Tang LY; Sun JY; Zhang WW; Li FY; Chen YX; He ZY
    Tumour Biol; 2017 Jun; 39(6):1010428317705082. PubMed ID: 28653887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.
    Ishitobi M; Okumura Y; Arima N; Yoshida A; Nakatsukasa K; Iwase T; Shien T; Masuda N; Tanaka S; Tanabe M; Tanaka T; Komoike Y; Taguchi T; Nishimura R; Inaji H
    Ann Surg Oncol; 2013 Jun; 20(6):1886-92. PubMed ID: 23292516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.